文献速递母胎医学

经皮硬化治疗宫内治疗伴水肿的II型和III型先天性肺气道畸形

Types II and III congenital pulmonary airway malformation with hydrops treated in utero with percutaneous sclerotherapy.
PubMed 文献 · Prenat Diagn · 2018-05-07

回顾性研究纳入8例产前诊断的II型或III型先天性肺气道畸形(CPAM)伴继发性水肿胎儿,接受5%乙醇胺油酸酯(EO)经皮硬化治疗。初次治疗孕周22.0周(19.6-31.4),3例接受2次操作。4例发生宫内胎死;存活4例分娩孕周38.4周(37.4-39.3),均行出生后切除。作者认为该疗法疗效仍存疑,需进一步研究确定最佳剂量及安全性。

要点

  • 8例CPAM II/III型伴水肿胎儿接受5% EO经皮硬化治疗,4例发生宫内胎死。
  • 存活者初次治疗EO用量3 mL(2-5),宫内胎死者为7 mL(6-10)。
  • 存活4例分娩孕周38.4周(37.4-39.3),均行出生后切除。

核心结论

  • 经皮硬化治疗对II型和III型CPAM的疗效仍存疑问,需进一步研究确定硬化剂最佳剂量及该操作的安全性和有效性。

研究设计与样本

  • 回顾性研究,纳入8例产前诊断CPAM II型或III型伴继发性水肿并接受5%乙醇胺油酸酯(EO)经皮硬化治疗的胎儿;所有患者均行超声测量CPAM体积比,结果以中位数(范围)表示。

主要发现

  • 初次硬化治疗孕周为22.0周(19.6-31.4),3例患者接受2次操作。
  • 4例发生宫内胎死;其中2例于术后第1天死亡(1例因意外血管内注射EO),2例于操作后超过6周死亡。
  • 存活者术前CPAM体积比为3.6(1.6-7.8),宫内胎死者为2.7(1.7-4.7)。
  • 存活者初次硬化治疗EO用量为3 mL(2-5),宫内胎死者为7 mL(6-10)。
  • 4例存活者分娩孕周为38.4周(37.4-39.3),均行出生后切除。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To present outcomes of fetuses with congenital pulmonary airway malformation (CPAM) treated with sclerotherapy. METHODS: Retrospective study of 8 patients with a prenatal diagnosis of CPAM type II or III with secondary hydrops treated with percutaneous sclerotherapy using 5% ethanolamine oleate (EO). All patients underwent ultrasonic measurement of the CPAM volume ratio. Results are expressed as median (range). RESULTS: Gestational age at initial sclerotherapy was 22.0 weeks (19.6-31.4); 3 patients underwent 2 procedures. Intrauterine fetal demise (IUFD) occurred in 4 cases; 2 died on postoperative day #1 (one from inadvertent intravascular EO injection); 2 died >6 weeks after the procedure. Preoperative CPAM volume ratio was 3.6 (1.6-7.8) in survivors and 2.7 (1.7-4.7) in those with IUFD. The volume of EO at the initial sclerotherapy procedure was 3 mL (2-5) in survivors and 7 mL (6-10) in IUFD cases. The gestational age at delivery of the 4 survivors was 38.4 weeks (37.4-39.3); all underwent postnatal resection. CONCLUSION: The efficacy of percutaneous sclerotherapy for CPAM types II and III remains in question. Further studies are needed to determine the optimal dose of sclerotherapy agent and the safety and efficacy of this procedure.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Chon AH, Korst LM, Abdel-Sattar M, et al. Types II and III congenital pulmonary airway malformation with hydrops treated in utero with percutaneous sclerotherapy. Prenat Diagn. 2018. PMID: 29665020. doi:10.1002/pd.5266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。